Brechbuhl et al. demonstrated that in ER+ breast cancers, CD146- CAFs suppressed ER expression, thus decreasing tumor cell sensitivity to estrogen and increasing resistance to tamoxifen, whereas CD146+ CAFs promoted ER expression, sustaining estrogen-dependent tumor proliferation and tamoxifen sensitivity [95]. This evidence concerns the gene ESR1 and breast carcinoma.